01—Abstract
Summary
Summary of the 10-Q filed October 31, 2024. Cited figures are marked; the original filing is the authoritative source.
Willis Towers Watson plc's third-quarter 2024 10-Q shows a sharp GAAP loss driven by the pending sale of its TRANZACT business.
Revenue for the three months ended September 30, 2024 was $2.29 billiona, up from $2.17 billion, and nine-month revenue was $6.90 billion versus $6.57 billion. Net loss attributable to WTW was $1.68 billion for the quarter (diluted loss per share of $16.44), compared with net income of $136 million a year earlier, and $1.34 billion for the nine months. The loss reflects a $1.04 billion goodwill impairment in the Benefits, Delivery and Administration reporting unit and a $1.19 billion loss on disposal, both tied to the agreement to sell TRANZACT for total cash consideration of $632 million, targeted for completion by December 31, 2024.
Excluding these and other adjusting items, the company reported adjusted operating income of $414 millionb for the quarter, up from $351 million, and adjusted EBITDA of $501 million, up from $436 million. Organic revenue growth was 6% for the quarter and 5% for the nine months. Adjusted diluted earnings per share were $2.93 versus $2.24 in the prior-year quarter.
Management noted that these adjusted measures are non-GAAP and exclude impairment, amortization, restructuring, transaction and transformation costs, and disposal gains and losses. On the balance sheet, cash and cash equivalents were $1.37 billionc at September 30, 2024, and total debt was $5.31 billion, with the capitalization ratio rising to 41.5% from 35.4% at year-end 2023. Operating cash flow was $913 million for the nine months, and free cash flow was $807 million.
The company repurchased $506 milliond of shares in the nine months and had approximately $837 million remaining under its repurchase authority. Quarterly dividends of $0.88 per share were declared, and the company issued $750 million of 5.900% senior notes due 2054 in March 2024, using proceeds to repay $650 million of 3.600% notes at maturity.
02—Key points
Key Highlights
- Revenue rose to $2.29 billion for Q3 2024 from $2.17 billion, an increase of 6% on both as-reported and organic bases; nine-month revenue was $6.90 billion, up 5%.
- Net loss attributable to WTW was $1.68 billion for Q3 2024 (diluted loss per share $16.44), versus net income of $136 million in Q3 2023, driven by the TRANZACT sale.
- A $1.04 billion goodwill impairment in the BDA reporting unit and a $1.19 billion pre-tax loss on disposal relate to the pending sale of TRANZACT for $632 million in cash.
- Adjusted operating income was $414 million for Q3 2024 versus $351 million, and adjusted EBITDA was $501 million versus $436 million (non-GAAP measures).
- Adjusted diluted earnings per share were $2.93 for Q3 2024 compared with $2.24 a year earlier.
- Cash and cash equivalents were $1.37 billion and total debt was $5.31 billion at September 30, 2024; the capitalization ratio increased to 41.5% from 35.4%.
- Nine-month operating cash flow of $913 million produced free cash flow of $807 million; the company repurchased $506 million of shares and had about $837 million of authorization remaining.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2024filed October 31, 2024Financial Statements
Q3 FY2024 against Q3 FY2023
| Line item | Q3 FY2024Q3 FY2023 | Change |
|---|---|---|
| Revenue | $2.29B$2.17B | +5.7% |
| Operating Expenses | $3.06B$2.01B | +52.2% |
| Operating Income | -$766.00M$159.00M | −581.8% |
| Interest Expense | $65.00M$61.00M | +6.6% |
| Net Income | -$1.68B$136.00M | −1331.6% |
| EPS (Basic) | $-16.44$1.30 | −1364.6% |
| EPS (Diluted) | $-16.44$1.29 | −1374.4% |
| Shares Outstanding (Basic) | 102.00M105.00M | −2.9% |
| Shares Outstanding (Diluted) | 102.00M105.00M | −2.9% |
05—Questions
Frequently Asked Questions
Why did WTW report a large net loss in the third quarter of 2024?
The net loss of $1.68 billion attributable to WTW was driven by the pending sale of TRANZACT, including a $1.04 billion goodwill impairment in the Benefits, Delivery and Administration reporting unit and a $1.19 billion loss on disposal. These are non-cash items tied to reclassifying TRANZACT as held for sale and adjusting its carrying value to fair value less costs to dispose.
What is the status and expected timing of the TRANZACT sale?
WTW entered into an agreement effective September 30, 2024 to sell TRANZACT for total cash consideration of $632 million, subject to adjustments. Completion is subject to regulatory approvals, including under the U.S. Hart-Scott-Rodino Act, and other customary conditions, and is targeted for completion by December 31, 2024. The filing notes that held-for-sale accounting requires further adjustments to carrying value until closing, which could produce additional losses.
How did core operating performance trend apart from the TRANZACT charges?
Revenue grew 6% organically in the quarter and 5% for the nine months, driven by strong performances in both the Health, Wealth & Career and Risk & Broking segments. Adjusted operating income rose to $414 million from $351 million, and adjusted EBITDA rose to $501 million from $436 million. Management attributed these increases mainly to higher revenue, partly offset by higher salary and incentive and benefit costs.
How is WTW's balance sheet and liquidity position?
At September 30, 2024, cash and cash equivalents totaled $1.37 billion and total debt was $5.31 billion, with all of the $1.5 billion revolving credit facility available. Total WTW shareholders' equity fell to $7.49 billion from $9.52 billion at year-end 2023. The company stated it believes it has sufficient liquidity for the next twelve months and was in compliance with all financial covenants.
How is WTW returning capital to shareholders?
During the nine months ended September 30, 2024, WTW repurchased $506 million of shares and paid $265 million in dividends. The board declared a quarterly dividend of $0.88 per share ($3.52 annualized), paid October 15, 2024. Approximately $837 million remained on the current open-ended repurchase authority at September 30, 2024.
06—Continue